Bellerophon Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview

Bellerophon Therapeutics

01/11/2021 11:38

* Bellerophon Therapeutics Inc  BLPH.OQ   BLPH.O  is expected
to show no change in quarterly revenue when it reports
results on November 3 (estimated). 
​* Refinitiv's mean analyst estimate for Bellerophon
Therapeutics Inc is for a loss of 63 cents per share. For the
same quarter last year, the company reported a loss of 84 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Bellerophon
Therapeutics Inc is $26​, about 86.4% above​ its last closing
price of $3.54. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.61       -0.66      -0.36     Beat    45.2
 Mar. 31 2021  -0.71       -0.71      -0.58     Beat    18.3
 Dec. 31 2020              -0.90      -0.86     Beat    4.8​
 Sep. 30 2020  -0.87       -0.83      -0.84     Missed  -0.9
 Jun.          -0.72​      -0.72      -0.51     Beat    29.2​
 30​ 2020​                                              
 Mar. 31 2020  -0.98       -1.01      -1.08     Missed  -6.4​
 Dec. 31 2019  -1.05       -1.05      -1.00     Beat    4.8
 Sep. 30 2019  -1.10       -1.10      -0.90     Beat    18.2
 This summary was machine generated November 1 at 11:38 GMT.  All
figures in US dollars unless otherwise stated